226H細胞
數量： 大量
是否是腫瘤細胞： 0
物種來源： 小鼠
細胞形態： **樣
**類型： IgG1; kappa light chain
運輸方式： 凍存運輸
生長狀態： 懸浮生長
ATCC Number： HB-12592?
Designations: 226H
226H細胞Depositors: ICOS Corporation
Isotype: IgG1; kappa light chain
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Cellular Products: immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. 226H細胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Animals were immunized with purified rat alphaD subunit. [56177]
Spleen cells were fused with NS-1 mouse myeloma cells.
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: 226H細胞Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
References: 56177: Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001
57779: Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. 226H細胞PubMed: 11031083
